Evogene reports Q2 cont ops EPS (50c) vs. (85c) last year

Reports Q2 revenue $884,000 vs. $605,000 last year. Ofer Haviv, Evogene’s (EVGN) President and CEO stated: “Evogene is entering a transformative phase, centered on the strategic repositioning of our business around ChemPass AI – a proprietary, cutting-edge platform for the AI-driven discovery and optimization of small molecules. With a renewed focus on high-impact innovation, cross-industry collaboration, and operational efficiency, Evogene is now uniquely positioned to unlock long-term value in two massive global markets- pharmaceuticals and agriculture.”